KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Debt (2017 - 2026)

Aquestive Therapeutics has reported Total Debt over the past 9 years, most recently at $37.5 million for Q4 2025.

  • For Q4 2025, Total Debt rose 15.33% year-over-year to $37.5 million; the TTM value through Dec 2025 reached $37.5 million, up 15.33%, while the annual FY2025 figure was $37.5 million, 15.33% up from the prior year.
  • Total Debt for Q4 2025 was $37.5 million at Aquestive Therapeutics, up from $36.3 million in the prior quarter.
  • Over five years, Total Debt peaked at $54.2 million in Q1 2022 and troughed at $16.1 million in Q1 2024.
  • A 5-year average of $39.2 million and a median of $38.6 million in 2021 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: crashed 61.92% in 2024 and later soared 109.22% in 2025.
  • Year by year, Total Debt stood at $53.6 million in 2021, then decreased by 2.67% to $52.1 million in 2022, then tumbled by 47.21% to $27.5 million in 2023, then increased by 18.15% to $32.5 million in 2024, then grew by 15.33% to $37.5 million in 2025.
  • Business Quant data shows Total Debt for AQST at $37.5 million in Q4 2025, $36.3 million in Q3 2025, and $35.0 million in Q2 2025.